Published in Cancer Weekly, November 12th, 2002
Satraplatin phase II studies have been successfully completed for the treatment of hormone-resistant prostate cancer, as well as other tumor types. GPC Biotech expects to begin phase III clinical development of satraplatin for the treatment of hormone-resistant prostate cancer in 2003, with clinical trials to be conducted in both the U.S. and Europe.
Bernd R. Seizinger, MD, PhD, GPC Biotech, said,...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.